MINOCA: When You Have a Heart Attack but Your Arteries Look Clean

A patient is admitted to the hospital with classic chest pain. The troponin comes back elevated. The EKG shows changes that look ischemic. The cardiologist tells the family this is a heart attack and takes the patient to the cath lab. Then, on angiogram, the coronaries look clean. No 90 percent blockage. No stent placed. The family is confused. The patient is confused. Sometimes the team taking care of the patient is confused. The discharge paperwork uses a word the patient has never heard before: MINOCA.

I'm Dr. Damian Rasch, a cardiologist in Encinitas. MINOCA stands for Myocardial Infarction with Non-Obstructive Coronary Arteries. It's a real heart attack, but the cause isn't a fixed plaque blocking a major artery, which is the picture most people carry in their heads when they hear the words "heart attack." This article walks through what MINOCA is, why it happens, how we figure out the cause, and what the treatment looks like once we know what we're dealing with. The reason it matters is that the workup and the long-term plan depend almost entirely on the underlying mechanism, and a generic "heart attack" treatment plan doesn't always fit.

The Definition: A Heart Attack Without an Obvious Blockage

A type 1 myocardial infarction means heart muscle damage caused by a sudden interruption of blood supply: the troponin biomarker rises, there are symptoms or EKG changes or imaging findings consistent with ischemia, and on angiogram you find a tight blockage that explains it. That's the textbook story, and it's still the most common one.

MINOCA is the same picture clinically (rising troponin, symptoms, EKG or wall motion changes consistent with infarction) but the angiogram doesn't show a culprit lesion of fifty percent or greater. The vessels look smooth or near-smooth. Yet the patient is undeniably injured. The heart muscle has had something happen to it, and the question shifts from "how do we open the blocked artery" to "what just hurt this heart?"

The numbers matter for context. Roughly six to ten percent of patients who walk into the emergency room with what looks like a heart attack turn out to have MINOCA on angiography. That fraction climbs to fifteen percent in some series, especially among younger patients and women. So this is not a rare diagnosis, even though it gets less attention than classic obstructive coronary disease.

Before we go further, an important distinction: MINOCA is a working diagnosis, not a final one. It tells you that the angiogram looked clean. It doesn't tell you why the heart got hurt. The whole point of the workup that follows is to identify the underlying mechanism, because every mechanism has a different treatment and a different long-term prognosis. Stopping at "MINOCA" without working out the cause is like stopping at "fever" without working out why.

Why It Happens: The Five Main Mechanisms

When I sit down with a patient who has just been told they have MINOCA, the first thing I explain is that there are several different things this label can hide. The 2019 American Heart Association scientific statement on MINOCA grouped the underlying causes into five main buckets. Most patients fall into one of them.

1. Plaque Disruption with Autolysis

This is probably the most common cause and the easiest to misread on angiogram. A small atherosclerotic plaque, often one that wouldn't have been considered hemodynamically significant, ruptures or erodes. A clot forms on top of it. The clot temporarily blocks the artery, the heart muscle downstream gets injured, and the patient develops symptoms. Then, by the time we get the patient to the cath lab, the body's own clot-busting machinery has already started chewing the thrombus down. By the time we shoot dye, there's nothing dramatic to see.

Intravascular imaging, either intravascular ultrasound (IVUS) or, more often these days, optical coherence tomography (OCT), can pick up the residual signature of plaque rupture or erosion that a regular angiogram misses. OCT, with its very high resolution, can identify a torn fibrous cap, a residual layer of thrombus, or an eroded plaque surface even after the visible blockage has cleared. When we find this, we treat the patient as if they had classic coronary disease: dual antiplatelet therapy, a high-intensity statin, blood pressure and diabetes optimization, and aggressive lifestyle modification. Plaque disruption MINOCA is a heart attack from the same biology as obstructive disease, just caught at a moment when the angio happens to look misleadingly clean.

2. Coronary Vasospasm

Sometimes the artery itself goes into spasm and squeezes shut, choking off blood flow even though there's no fixed plaque. This was originally described as Prinzmetal's angina back in 1959, and it's still a real entity. Patients with vasospasm tend to have symptoms at rest, often in the early morning hours. They may have a history of migraines or Raynaud's phenomenon, both of which involve vascular reactivity. Cocaine, methamphetamine, and certain chemotherapy drugs can also provoke spasm.

The diagnostic gold standard is provocation testing in the cath lab using intracoronary acetylcholine. We inject the drug into the coronary artery and watch for inducible spasm with a corresponding EKG change and reproduction of symptoms. This is a sensitive but somewhat invasive test, and not every cath lab does it routinely. Treatment for confirmed vasospasm is a calcium channel blocker (usually amlodipine or diltiazem), often combined with a long-acting nitrate. Smoking cessation is mandatory because nicotine is a strong spasm trigger. Beta-blockers, especially nonselective ones, can actually make spasm worse and are usually avoided.

3. Coronary Microvascular Dysfunction

The third mechanism involves the smallest blood vessels in the heart, the ones too small to see on angiogram. The microvasculature handles the final delivery of blood to the heart muscle, and when it's not working properly, the heart can become ischemic even though the big arteries are wide open. Microvascular dysfunction is more common in women, in patients with diabetes, in those with longstanding hypertension, and in patients with autoimmune conditions like lupus or rheumatoid arthritis.

Diagnosing microvascular dysfunction requires specialized testing, often coronary flow reserve measurement or microvascular resistance index using a pressure wire in the cath lab. PET myocardial perfusion imaging with quantitative flow measurement is another option in centers that have it. Treatment overlaps with treatment for stable angina: anti-anginal medications like ranolazine, beta-blockers (which are fine here, unlike in vasospasm), calcium channel blockers, ACE inhibitors or ARBs, and statin therapy. Lifestyle changes that improve endothelial function, especially exercise, cardiac rehabilitation, and Mediterranean-style diets, also help.

4. Spontaneous Coronary Artery Dissection (SCAD)

SCAD deserves its own mention because it's increasingly recognized as a frequent cause of MINOCA, especially in younger women. The mechanism is a tear in the inner layer of the coronary artery wall, with blood seeping into the layers and forming an intramural hematoma that compresses the lumen from within. It can mimic atherosclerosis on angiogram, but it isn't atherosclerosis at all, and the treatment is very different.

If we identify SCAD, we usually prefer a conservative approach: medical therapy, no stent if at all possible, careful blood pressure control, and avoidance of intense isometric exercise during the healing phase. Stenting a SCAD lesion can extend the dissection and is reserved for patients with ongoing ischemia or hemodynamic instability. SCAD has its own dedicated evaluation pathway, including screening for fibromuscular dysplasia in other vascular beds, and I have a separate article devoted to it on the site.

5. Coronary Embolism or Thrombosis

A clot or piece of debris from somewhere else in the body can travel into a coronary artery and block it briefly before either dissolving or moving downstream. The most common source in older patients is the left atrial appendage in atrial fibrillation. Other sources include valvular vegetations from endocarditis, mechanical prosthetic valves without adequate anticoagulation, paradoxical embolism through a patent foramen ovale or atrial septal defect, and inherited or acquired hypercoagulable states.

Workup here is broader than just the heart. We look at rhythm (is there occult AFib?), at the heart valves with a transesophageal echocardiogram if endocarditis is on the differential, and at the patient's clotting profile, including testing for antiphospholipid antibodies, factor V Leiden, prothrombin gene mutations, and other thrombophilias when the clinical scenario fits. Treatment is anticoagulation, often long-term, and management of whatever underlying source caused the embolism.

Why the Mechanism Matters So Much

When patients ask me why we go through all this extra testing instead of just calling it a heart attack and starting standard medications, the answer is that the treatments diverge sharply depending on what's causing the problem.

A patient with plaque disruption MINOCA needs aggressive antiplatelet and statin therapy because the underlying biology is identical to atherosclerotic coronary disease. A patient with vasospastic MINOCA needs calcium channel blockers and nitrates and benefits very little from antiplatelet medications. A patient with embolic MINOCA from atrial fibrillation needs lifelong anticoagulation. A patient with SCAD needs conservative management and avoidance of stents whenever possible. Picking the wrong path can mean either undertreating the actual problem or exposing the patient to medications and procedures they don't need.

There's also a prognostic dimension. The five mechanisms have different long-term outcomes. Plaque disruption MINOCA carries a roughly similar long-term mortality risk to obstructive MI if treated appropriately. SCAD has its own course, with a recurrence risk that gets factored into surveillance. Microvascular dysfunction is associated with progressive heart failure with preserved ejection fraction in a subset of patients. The numbers we use to counsel patients about long-term risk depend on which specific mechanism we're treating.

The Workup, Step by Step

When a patient comes in with what looks like a MINOCA picture, the workup proceeds in a fairly standard order, although the specific tests depend on what's most likely based on history.

The starting point is always making sure the diagnosis is correct in the first place. A rising troponin without obstructive coronary disease can come from things that aren't heart attacks at all. Myocarditis is the big mimic here. Takotsubo cardiomyopathy, also called stress cardiomyopathy, can produce a similar picture. A pulmonary embolism large enough to strain the right heart can elevate troponin and cause EKG changes. Sepsis can do it. Severe hypertensive emergency can do it. So step one is making sure we're actually dealing with infarction biology and not one of these alternate diagnoses, because the management is completely different.

Cardiac MRI is the workhorse test for sorting that question out. The pattern of late gadolinium enhancement, when present, tells us a great deal. A subendocardial pattern suggests true infarction. A patchy mid-myocardial pattern suggests myocarditis. A circumferential subepicardial pattern suggests a different inflammatory process. Takotsubo has its own characteristic apical or mid-ventricular wall motion pattern that resolves over weeks. CMR is so useful in this scenario that recent guidelines effectively recommend it in every MINOCA patient who can tolerate the test, ideally within a week or two of the event.

If CMR confirms infarction biology, we then look for the mechanism. Intravascular imaging (IVUS or OCT) of any suspicious areas on the angiogram, even if they didn't look like obstruction, can identify plaque disruption or SCAD. Provocation testing with acetylcholine identifies vasospasm. Microvascular function testing with a pressure wire identifies microvascular dysfunction. A holter monitor or implantable loop recorder, depending on suspicion, looks for occult atrial fibrillation as a source of embolism. A transesophageal echocardiogram looks for valvular and septal sources. Hypercoagulability labs round out the embolic workup.

Not every patient gets every test. We tailor the workup to the clinical picture. A 35-year-old woman who had a MINOCA event two weeks postpartum gets a different workup than a 70-year-old man with a fifty-pack-year smoking history. But in both cases, we keep digging until we have a mechanism.

Treatment, by Mechanism

Once we have the mechanism, the treatment usually becomes straightforward.

For plaque disruption MINOCA, the treatment is the same as for any other ischemic heart disease patient. Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor like clopidogrel or ticagrelor) for at least a year, then aspirin alone indefinitely. A high-intensity statin to drive LDL well below 70 mg/dL. Blood pressure control. Diabetes optimization. Smoking cessation if relevant. Cardiac rehabilitation. The heart-healthy diet. Exercise. Sometimes an ACE inhibitor or ARB if there's any LV dysfunction or hypertension. The whole package.

For vasospastic MINOCA, the foundation is a calcium channel blocker. Amlodipine 5 to 10 mg daily, or diltiazem 240 to 360 mg daily, often does the job. A long-acting nitrate added in patients who continue to have symptoms despite the calcium blocker. Smoking cessation. Avoiding triggers like cocaine and amphetamines. Stress management. Beta-blockers, especially nonselective ones like propranolol, are usually avoided because they can leave alpha-mediated vasoconstriction unopposed and worsen spasm.

For microvascular MINOCA, the treatment overlaps with stable angina. Beta-blockers (which are useful here), calcium channel blockers, ranolazine for refractory angina, ACE inhibitors or ARBs, statins, and aspirin. Lifestyle is huge. Cardiac rehabilitation produces real, measurable improvements in microvascular function. Mediterranean dietary patterns and regular aerobic exercise are powerful tools.

For SCAD, the conservative path is the right path for most patients. Beta-blockers to reduce shear stress on the healing vessel wall. Tight blood pressure control. Avoidance of strenuous isometric exercise (heavy lifting, intense Valsalva maneuvers) for at least a year. Aspirin is often continued, though dual antiplatelet therapy is no longer routinely recommended for SCAD without stenting. Screening for fibromuscular dysplasia in the renal, cervical, and intracranial arteries, since the two conditions travel together in roughly half of SCAD patients.

For embolic MINOCA, treatment depends on the source. If atrial fibrillation is the source, lifelong anticoagulation with a DOAC like apixaban or rivaroxaban, plus rate or rhythm control. If endocarditis is the source, antibiotic therapy and sometimes valve surgery. If a hypercoagulable state is the source, often lifelong anticoagulation with management decisions tailored to the specific thrombophilia. If a patent foramen ovale is the source in a young patient with a documented paradoxical embolism, sometimes percutaneous closure.

Prognosis: Better Than Classic MI, but Not Benign

A common misunderstanding is that MINOCA, because it doesn't involve a tight blockage, must be a milder version of a heart attack. That's not quite right. The injury to the heart muscle is real, and the long-term outlook depends heavily on the mechanism.

Pooled data from large MINOCA registries suggest a one-year mortality of about three to five percent, which is lower than mortality after classic obstructive MI but higher than the general population's baseline. Recurrent MI is reported in roughly five to ten percent of MINOCA patients in the year after the index event. Heart failure develops in a meaningful subset, especially when the underlying mechanism is microvascular dysfunction or untreated vasospasm.

The numbers improve dramatically when treatment is matched to the mechanism. Patients with plaque disruption MINOCA who are treated with appropriate antiplatelet and statin therapy do roughly as well as obstructive MI patients with stenting. Patients with vasospastic MINOCA who are on adequate calcium channel blocker therapy and have stopped smoking usually do well. The patients who get into trouble are usually the ones who were given a generic "heart attack" workup with no further investigation, prescribed a beta-blocker and an aspirin, and sent on their way without anyone identifying what actually caused the event.

This is why I push for a complete mechanism workup in every MINOCA patient, even though it sometimes means staying in the hospital an extra day for a CMR or scheduling a follow-up cath for provocation testing. The information we get drives decisions for the next twenty or thirty years of the patient's care.

When to Push Your Doctor for More

If you or someone you love has been told they had a MINOCA event, here are the questions worth asking before discharge or at the first follow-up appointment.

First: was a cardiac MRI done? If not, why not? If the answer is "we didn't think it was necessary," push for an explanation. CMR is the single most useful test for sorting out the cause and ruling out the major mimics. It should be done in nearly every MINOCA patient.

Second: was intravascular imaging done during the catheterization? OCT or IVUS can identify plaque erosion or rupture that a standard angiogram misses. If it wasn't done, ask whether a repeat cath with imaging is appropriate.

Third: was provocation testing for vasospasm considered? This applies especially to patients whose symptoms occurred at rest, in the early morning, or in the absence of exertion.

Fourth: was a hypercoagulability workup done? This applies especially to younger patients, women with a history of pregnancy losses, and anyone with a personal or family history of clotting events.

Fifth: what's the long-term plan? What mechanism is being treated, and which medications are targeting that mechanism? "We're putting you on a heart attack regimen" is not a complete answer. The medications should be matched to the specific cause.

When to Escalate Care

If you have already had a MINOCA event and you develop new chest pain, especially at rest, or new shortness of breath, or palpitations, get evaluated promptly. The recurrence risk is real, and the threshold for re-evaluation is lower than it would be in someone without a prior event.

Call 911 if you have severe chest pain at rest, severe shortness of breath, palpitations with lightheadedness, or any combination of those. The same rules that apply to anyone with possible cardiac symptoms apply here, with the added consideration that you have already proven your heart vulnerable to ischemic injury.

Contact your cardiologist within twenty-four hours for new mild chest pain, new exertional shortness of breath, new palpitations without other symptoms, or any concern that something might be off. Most of these calls turn out to be reassuring, and the ones that don't are caught earlier than they would have been otherwise.

Common Patient Questions

My doctor said my arteries were "clean" but I had a heart attack. How is that possible?

It's possible because not every heart attack is caused by a fixed plaque blocking a major artery. Plaques can rupture and the body can dissolve the resulting clot before angiography. Arteries can spasm. The smallest vessels in the heart can fail to deliver blood properly even when the big ones look fine. Clots can travel from elsewhere in the body. A coronary artery wall can tear from the inside without external pressure. All of these can produce a heart attack on the lab values and EKG without producing an obvious blockage on angiogram. The angiogram only shows the lumen of the larger vessels. It doesn't show the small ones, doesn't show what happened a few hours ago, and doesn't always show plaque biology.

Do I really need to be on all these medications if my arteries are clean?

It depends on what caused your event. If you had plaque disruption that lysed before the cath, then yes, you need the same medical regimen as any other coronary disease patient, because the underlying biology is identical. If you had vasospasm, the medication list is different but no less important, just oriented around calcium channel blockers and nitrates instead of antiplatelets. If you had an embolic event from atrial fibrillation, you need anticoagulation. The point is that you need treatment matched to your specific mechanism, not a generic "heart attack regimen" or, worse, no medication at all.

Can MINOCA happen again?

Yes, recurrence is real. The numbers vary by mechanism and by how well the underlying cause is treated, but a reasonable estimate is that about five to ten percent of MINOCA patients will have another event within the first year if they're not on optimized therapy. With appropriate mechanism-targeted treatment, that number drops substantially. The biggest predictor of recurrence is leaving the underlying cause untreated, which is why the diagnostic workup matters so much.

Should I get cardiac rehab after a MINOCA event?

Almost always, yes. Cardiac rehabilitation is one of the most under-utilized interventions in modern cardiology. It improves exercise capacity, helps with risk factor modification, addresses the anxiety and depression that often follow a cardiac event, and produces measurable improvements in microvascular function in patients who have it. It's safe in nearly every MINOCA mechanism, with rare exceptions like active SCAD healing. If you've had a MINOCA event and you weren't offered cardiac rehab, ask about it.

My doctor mentioned cocaine in passing. Why?

Cocaine, methamphetamine, and certain other stimulants are classic triggers of coronary vasospasm and can also accelerate plaque rupture. We ask about them in every MINOCA patient, not because we assume use, but because identifying a substance trigger completely changes management. If a patient has a vasospastic MINOCA event triggered by cocaine, the most important treatment is stopping cocaine, not just adding a calcium channel blocker. The same is true for methamphetamine. We ask without judgment because the answer matters.

I'm a younger woman. Why did this happen to me?

Younger women are over-represented in MINOCA series for a few reasons. SCAD is far more common in women than men, especially in women under fifty. Microvascular dysfunction is more common in women across the age spectrum. Vasospasm has a slight female predominance. And women are sometimes worked up less aggressively for traditional plaque disease before being labeled MINOCA, so a fraction of cases that should have been picked up as obstructive disease end up in the MINOCA category. The right move is a careful, mechanism-focused workup, including consideration of SCAD, microvascular disease, and pregnancy-related causes if relevant.

Is MINOCA hereditary?

Most MINOCA mechanisms aren't hereditary in a simple Mendelian sense, but family history matters in several ways. Atherosclerotic disease has a clear hereditary component, and plaque disruption MINOCA shares that biology. SCAD has been linked to fibromuscular dysplasia, which has familial clustering and recently identified genetic associations. Some hypercoagulable states (factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome) have a hereditary component. So while there isn't a single "MINOCA gene," family history can shape the workup and the screening recommendations for siblings and children.

A Final Note From Me

MINOCA used to be a frustrating diagnosis. The angiogram looked clean, the patient went home on a beta-blocker and aspirin, and nobody really knew what had happened. That's changed dramatically over the last fifteen years. We now have the imaging technology to identify plaque biology that the dye doesn't show. We have provocation testing protocols that can confirm vasospasm. We have CMR to differentiate infarction from myocarditis from takotsubo. We have a much richer understanding of microvascular dysfunction. And we have a clear consensus, codified in the AHA scientific statement and the ESC guidelines, that MINOCA needs a mechanism-driven workup, not a generic ischemic heart disease pathway.

If you've been given the MINOCA diagnosis, the most important thing is to make sure the workup gets done. The label by itself isn't an answer. It's an invitation to keep digging. Once the underlying mechanism is identified, the treatment plan usually comes together quickly, and the long-term outlook is much better than it was a generation ago. The patients I worry about are the ones who never got past "your arteries looked fine" and who are walking around with an unidentified, untreated cause of cardiac injury. The ones I'm hopeful about are the ones who get a complete workup, a clear mechanism, and a targeted treatment plan.

If you've had a heart attack and the angiogram came back clean, ask the questions in this article. Ask about the CMR. Ask about intravascular imaging. Ask about provocation testing. Ask about hypercoagulability. The answers shape what your care looks like for decades to come.

References

1. Tamis-Holland, Jacqueline E., Harmony R. Reynolds, Loredana Agewall, et al. "Contemporary Diagnosis and Management of Patients with Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement from the American Heart Association." Circulation 139, no. 18 (2019): e891-e908.

2. Pasupathy, Sivabaskari, Tracey Air, Rosanna C. Dreyer, Rosie Tavella, and John F. Beltrame. "Systematic Review of Patients Presenting with Suspected Myocardial Infarction and Nonobstructive Coronary Arteries." Circulation 131, no. 10 (2015): 861-870.

3. Reynolds, Harmony R., Mary N. Maehara, Roxana Mehran, et al. "Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction with Nonobstructive Coronary Arteries in Women." Circulation 143, no. 7 (2021): 624-640.

4. Thygesen, Kristian, Joseph S. Alpert, Allan S. Jaffe, et al. "Fourth Universal Definition of Myocardial Infarction (2018)." Journal of the American College of Cardiology 72, no. 18 (2018): 2231-2264.

5. Collet, Jean-Philippe, Holger Thiele, Emanuele Barbato, et al. "2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation." European Heart Journal 42, no. 14 (2021): 1289-1367.

6. Hayes, Sharonne N., Esther S. H. Kim, Jacqueline Saw, et al. "Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement from the American Heart Association." Circulation 137, no. 19 (2018): e523-e557.

7. Bairey Merz, C. Noel, Carl J. Pepine, Mary N. Walsh, and Jerome L. Fleg. "Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade." Circulation 135, no. 11 (2017): 1075-1092.

8. Jansen, Tijn P. J., Peter Damman, Sander Elias, et al. "Diagnostic Approach to Patients with Myocardial Infarction and Non-Obstructive Coronary Arteries." European Heart Journal 43, no. 12 (2022): 1112-1124.

9. Lindahl, Bertil, Tomasz Baron, Daniel Erlinge, et al. "Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients with Myocardial Infarction with Nonobstructive Coronary Artery Disease." Circulation 135, no. 16 (2017): 1481-1489.

10. Beltrame, John F., Filippo Crea, Juan Carlos Kaski, et al. "International Standardization of Diagnostic Criteria for Vasospastic Angina." European Heart Journal 38, no. 33 (2017): 2565-2568.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.